Susquehanna International Group
NVCT icon

Susquehanna International Group’s Nuvectis Pharma NVCT Stock Holding History

Susquehanna International Group’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-60,600
Closed -$458K – 13828
2025
Q4 		$458K Buy
+60,600
New +$395K ﹤0.01% 9003
2025
Q3 		– Sell
-50,100
Closed -$374K – 13438
2025
Q2 		$374K Sell
50,100
-26,300
-34% -$238K ﹤0.01% 9846
2025
Q1 		$746K Buy
+76,400
New +$550K ﹤0.01% 7993

Other funds holding NVCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Susquehanna International Group's NVCT Position: Q1 2026 in Review

Susquehanna International Group reduced its Nuvectis Pharma (NVCT) stake by 22% in Q1 2026, selling an estimated $247K and leaving 105,286 shares worth $814K. The position accounts for ﹤0.01% of the portfolio, ranked #8429.

Susquehanna International Group first reported a position in NVCT in Q4 2023 and has held it in 7 quarters since. The position peaked at $1.01M in Q4 2025. 62 funds tracked by Wall St. Rank hold NVCT as of Q1 2026.

  • Susquehanna International Group held 105,286 shares of Nuvectis Pharma worth $814K as of Q1 2026.
  • Susquehanna International Group sold 28,868 Nuvectis Pharma shares in Q1 2026, an estimated $247K.
  • Nuvectis Pharma made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #8429 holding.
  • Susquehanna International Group first reported a position in Nuvectis Pharma in Q4 2023 and has held it in 7 quarters since.
  • Susquehanna International Group's Nuvectis Pharma position peaked at $1.01M in Q4 2025.
  • 62 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.